MedTrace Logo

Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus

NCT03758079 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2018-11-29

No results posted yet for this study

Summary

This is a single blind randomized trial to compare efficacy and side effects of Gabapentin with Doxepin. Hemodialysis patients with uremic pruritus at one dialysis center of Saint George Hospital University Medical Centre were included in this study. Patients were divided into 2 groups to receive either 10 mg Doxepin daily or Gabapentin at a dose of 100mg after each hemodialysis session (increased as tolerated) for 4 weeks, after which patients were treated reversley. Pruritus severity and its effect on quality of life will be assessed by using visual analog scale (VAS), 5-D pruritus scale and dermatology life quality index (DLQI). Include patients will have to fill these forms at baseline and at end of week1, week2 and week4

Conditions

  • Uremic Pruritus

Interventions

DRUG

Doxepin

10 mg Doxepin for 4 weeks

DRUG

Gabapentin

dose of 100mg after each hemodialysis session (increased as tolerated) for 4 weeks

Sponsors & Collaborators

  • University of Balamand

    lead OTHER

Principal Investigators

  • Roger N Haber, MD · University of Balamand/Saint George Hospital University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2018-10-08
Completion
2018-10-08
FDA Drug
Yes

Countries

  • Lebanon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03758079 on ClinicalTrials.gov